None listed
Conditions
Interventions
Day0, 1 day oral intake of 900mg of Carnosine. Day1-6, Oral intake of 1g of plant-derived components everyday. Day7, 1day oral intake of 900mg of Carnosine &
1g of plant-derived components.
Sponsors
Suntory Global Innovation Center Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Healthy males and females aged 20 to less than 60 years old. 2)Subjects who can make self-judgment and are voluntarily giving written informed consent.
Exclusion criteria
Exclusion criteria: 1)Subjects who take continuous medical treatment. 2)Subjects who are contracting with diabetic nephropathy 3)Subjects who constantly use supplements and/or functional foods (including Food for Specified Health Uses) affecting the test results. 4)Subjects who have contracted or are contracting heart disease, liver disease, kidney disease and digestive disease. 5)Subjects who have contracted with cancer 6)Subjects who are pregnant or have possibility to bocome pregnant or planning to become pregnant during the study or breast-feeding woman. 7)Subjects who drink alcohol a lot 8)Subjects who have an extremely irregular diet habit or alternative work schedule or work on midnight shift 9)Subjects who have allergic reaction to drug medicine and food. 10)Subjects who have systolic blood pressure less than 90 mmHg. 11)Subjects who donated 200 mL of blood and/or blood components within the last one month prior to the current study. 12)Male subjects who donated 400 mL of blood within the last three months prior to the current study. 13)Female subjects who donated 400 mL of blood within the last four months prior to the current study. 14)Male subjects whose blood was collected more than 1200 mL within the last twelve months when the amount of blood sampling in the current study is added. 15)Female subjects whose blood was collected more than 800 mL within the last twelve months when the amount of blood sampling in the current study is added. 16)Subjects who are participating in other clinical studies for drug medicine or food, or who finished clinical study within four weeks, or who are planning to participate in other clinical study. 17)Subjects who are judged as unsuitable for the study by the principal investigator for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy : Area under the curve of blood carnosine level after ingestion of carnosine Safety : Adverse effects | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy : Blood carnosine level at each blood sampling time after ingestion of carnosine Safety : Adverse events | — |
Countries
Japan
Contacts
Public ContactHiroshi Watanabe
Suntory Global Innovation Center Ltd. Innovation Development Department
Outcome results
None listed